Celsion Announces FDA Clearance of the OPTIMA Study - A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer
Study Developed in Consultation with Clinical Advisors, Statistical Experts and FDA
Compelling Survival Data Supports Development
Trial Advances Global Regulatory Strategy in Key Markets
LAWRENCEVILLE, N.J., Feb. 24, 2014 -- (Healthcare Sales & Ma... Biopharmaceuticals, Drug Delivery, Oncology, FDACelsion, ThermoDox, liposome, hepatocellular carcinoma, liver cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Legislation | Liver | Liver Cancer | Pharmaceuticals | Statistics | Study | Urology & Nephrology